ENGLEWOOD, Colo., Oct. 26,
2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE
American: AMPE), a biopharmaceutical company focused on the
advancement of immunology based therapies for prevalent
inflammatory conditions, announced today that the Company will
present at the 2020 MedTech Innovation Forum hosted by Roth
Capital Partners on Wednesday, October
28, 2020.
The Company's presentation will (i) review preliminary results
from the randomized, controlled study of intravenous
Ampion™ for treatment of hospitalized COVID-19
infected adult patients requiring supplemental oxygen and (ii)
further discuss its future COVID-19 plans. Ampion addition to
standard of care ("SOC") was compared to patients treated with the
SOC including anti-viral therapy ("remdesivir"). Safety was
determined by presence of adverse events during the trial and
indications of efficacy was determined by the Ordinal Scale, a
measure developed by the WHO (a range of 0-8, with 0 defined as
uninfected with no clinical or virological signs of infection and 8
denoting death) and calculated as a change from admission to
discharge or at the time of discharge from the hospital.
The primary end-point was safety and, as previously reported,
there were no drug related adverse events for a period of 5 days
subsequent to the treatment with Ampion. The secondary end point
was improvement in the score as measured by the Ordinal Scale.
Ampion addition to the SOC compared to the SOC alone or SOC plus
remdesivir, demonstrated that the addition of Ampion to the SOC
resulted in better average outcomes (reduction in 3 points for
Ampion+ SOC versus 1.5 and 2.25 points for SOC and SOC+remdesivir,
respectively). Average scores as measured by the Ordinal Scale at
the time of discharge from the hospital were also better for
Ampion+SOC compared to the other groups (a score of 1 for Ampion
+SOC versus 2.75 and 1.75 for SOC and SOC+remdesivir,
respectively).
About Ampio Pharmaceutical
Ampio Pharmaceuticals,
Inc. is a development stage biopharmaceutical company primarily
focused on the development of Ampion, our product candidate, to
treat prevalent inflammatory conditions for which there are limited
treatment options. Ampio's lead drug, Ampion, is backed by an
extensive patent portfolio with intellectual property protection
extending through 2032, and will be eligible for 12-year FDA market
exclusivity upon approval as a novel biologic under the biologics
price competition and innovation act ("BPCIA").
Forward Looking
Statements
Ampio's statements in
this press release that are not historical fact, and that relate to
future plans or events, are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by the use of words
such as "believe," "expect," "plan," "anticipate," and similar
expressions. These forward-looking statements include statements
regarding Ampio's expectations with respect to Ampion and its
classification, as well as those associated with regulatory
approvals and other FDA decisions, the Biological License
Application ("BLA"), the ability of Ampio to enter into
partnering arrangements, clinical trials and decisions and
changes in business conditions and similar events, the ability to
receive regulatory approval to conduct clinical trials, that Ampion
may be used to treat ARDS induced by COVID-19, all of which are
inherently subject to various risks and uncertainties. The risks
and uncertainties involved include those detailed from time to time
in Ampio's filings with the Securities and Exchange Commission,
including without limitation, under Ampio's Annual Report on Form
10-K and other documents filed with the Securities and Exchange
Commission. Ampio undertakes no obligation to revise or update
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Company Contact
Dan Stokely, CFO
Phone: (720) 437-6500
info@ampiopharma.com
Ampio Pharmaceuticals, Inc.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ampio-presents-at-roth-capital-partners-2020-medtech-innovation-forum-focusing-on-covid-19-clinical-trial-activities-301159523.html
SOURCE Ampio Pharmaceuticals, Inc.